Cellular vaccination of MLH1^−/− mice – an immunotherapeutic proof of concept study

References

• Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016;22(4):813–20. doi:10.1158/1078-0432.CCR-15-1678. PMID:26880610.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Woerner SM, Tosti E, Yuan YP, Kloor M, Bork P, Edelmann W, Gebert J. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors. Mol Carcinog. 2015;54(11):1376–86. doi:10.1002/mc.22213. PMID:25213383.
   PubMed Web of Science ®Google Scholar
• Speetjens FM, Lauwen MM, Franken KL, Janssen-van Rhijn CM, van Duikeren S, Bres SA, van de Velde CJ, Melief CJ, Kuppen PJ, van der Burg SH, et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer. 2008;123(4):838–45. doi:10.1002/ijc.23570. PMID:18506693.
   PubMed Web of Science ®Google Scholar
• Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 2017;403:159–64. doi:10.1016/j.canlet.2017.06.018. PMID:28645564.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Drescher K, Knezetic J, Lanspa S. Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review. Curr Treat Options Oncol. 2014;15(3):429–42. doi:10.1007/s11864-014-0293-5. PMID:24827900.
   PubMed Web of Science ®Google Scholar
• Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, Entz-Werle N, Goldberg Y, Ilencikova D, Kratz CP, et al. EU-Consortium Care for CMMR-D (C4CMMR-D). Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet. 2014;51(5):283–93. doi:10.1136/jmedgenet-2013-102238. PMID:24556086.
   PubMed Web of Science ®Google Scholar
• Maletzki C, Huehns M, Bauer I, Ripperger T, Mork MM, Vilar E, Klöcking S, Zettl H, Prall F, Linnebacher M. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome. Mol Carcinog. 2017;56(7):1753–64. doi:10.1002/mc.22632. PMID:28218421.
   PubMed Web of Science ®Google Scholar
• Maletzki C, Beyrich F, Hühns M, Klar E, Linnebacher M. The mutational profile and infiltration pattern of murine MLH1−/− tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget. 2016;7(33):53583–98. doi:10.18632/oncotarget.10677. PMID:27447752.
   PubMed Web of Science ®Google Scholar
• Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, Guilloux A, Chalastanis A, Lafitte P, Coulet F, et al. European Consortium “Care for CMMRD”. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology. 2015;149(4):1017–29. e3. doi:10.1053/j.gastro.2015.06.013. PMID:26116798.
   PubMed Web of Science ®Google Scholar
• Ryan E, Sheahan K, Creavin B, Mohan HM, Winter DC. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Crit Rev Oncol Hematol. 2017;116:38–57. doi:10.1016/j.critrevonc.2017.05.006. PMID:28693799.
   PubMed Web of Science ®Google Scholar
• Czink E, Kloor M, Goeppert B, Froehling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite unstable biliary tract cancer. Cold Spring Harb Mol Case Stud. 2017;3:a001974. doi:10.1101/mcs.a001974.
   PubMedGoogle Scholar
• Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von Knebel Doeberitz M, et al. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother. 2013;62(1):27–37. doi:10.1007/s00262-012-1303-8. PMID:22729559.
   PubMed Web of Science ®Google Scholar
• Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, Garbe Y, Tariverdian M, Findeisen P, Neumaier M, Holinski-Feder E, et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer. 2010;9(2):173–9. doi:10.1007/s10689-009-9307-z. PMID:19957108.
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988–97. doi:10.1053/j.gastro.2008.01.015. PMID:18395080.
   PubMed Web of Science ®Google Scholar
• Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24. doi:10.1111/imm.12675. Epub 2016 Oct 12.
   PubMed Web of Science ®Google Scholar
• Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother. 2012;61(9):1359–71. doi:10.1007/s00262-012-1321-6.
   PubMed Web of Science ®Google Scholar
• Hirata T, Yamamoto H, Taniguchi H, Horiuchi S, Oki M, Adachi Y, Imai K, Shinomura Y. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol. 2007;211(5):516–23. doi:10.1002/path.2142.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Coukos G, Kandalaft LE. Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel). 2015;3(2):344–72. doi:10.3390/vaccines3020344. PMID:26343191.
   PubMed Web of Science ®Google Scholar
• Bourdais R, Rousseau B, Pujals A, Boussion H, Joly C, Guillemin A, Baumgaertner I, Neuzillet C, Tournigand C. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Crit Rev Oncol Hematol. 2017 May;113:242–8. doi:10.1016/j.critrevonc.2017.03.027.
   PubMed Web of Science ®Google Scholar
• Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, Van Loo P, Tarpey PS, Coupland P, Behjati S, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47(3):257–62. doi:10.1038/ng.3202. PMID:25642631.
   PubMed Web of Science ®Google Scholar
• Linnebacher M, Maletzki C, Emmrich J, Kreikemeyer B. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. J Immunother. 2008;31(8):704–13. doi:10.1097/CJI.0b013e3181829f62. PMID:18779749.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19(6):796–807. doi:10.1093/neuonc/now287. PMID:28115578.
   PubMed Web of Science ®Google Scholar
• Wimmer K, Rosenbaum T, Messiaen L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet. 2017;91(4):507–19. doi:10.1111/cge.12904. PMID:27779754.
   PubMed Web of Science ®Google Scholar
• Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers. Eur J Cancer. 2013 Jul;49(11):2587–95. doi:10.1016/j.ejca.2013.02.035.
   PubMed Web of Science ®Google Scholar
• Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods Mol Biol. 2016;1403:755–61. doi:10.1007/978-1-4939-3387-7_43. PMID:27076165.
   PubMedGoogle Scholar
• Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology. 2017;6(4):e1302631. doi:10.1080/2162402X.2017.1302631. PMID:28507809.
   PubMed Web of Science ®Google Scholar
• Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016;34(19):2206–11. doi:10.1200/JCO.2016.66.6552. PMID:27001570.
   PubMed Web of Science ®Google Scholar
• Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, Hartmann E, Lange F, Maletzki C, Linnebacher M, et al. Application of in vivo imaging techniques to monitor therapeutic efficiency of vemurafenib in an experimental model of microsatellite instable colorectal cancer. Oncotarget. 2017;8:69756–67. doi:10.18632/oncotarget.19263.
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Yamamoto T, Matsumura A. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurol Med Chir (Tokyo). 2017;57(7):321–30. doi:10.2176/nmc.nmc.ra.2016-0334.
   PubMed Web of Science ®Google Scholar
• Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, Folliot P, Chalastanis A, Muleris M, Hamelin R, et al. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. Int J Cancer. 2009;125(10):2360–6. doi:10.1002/ijc.24681. PMID:19551857.
   PubMed Web of Science ®Google Scholar
• Tian Y, Li M, Yu C, Zhang R, Zhang X, Huang R, Lu L, Yuan F, Fan Y, Zhou B, et al. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget. 2017;8(28):45951–64. doi:10.18632/oncotarget.17504.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Schlick E, Ruffmann R, Wiltrout RH, Chirigos MA. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 1985;45(3):1058–65.
   PubMed Web of Science ®Google Scholar
• Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89. doi:10.1186/1479-5876-11-89. PMID:23557194.
   PubMed Web of Science ®Google Scholar
• Péron S, Metin A, Gardès P, Alyanakian MA, Sheridan E, Kratz CP, Fischer A, Durandy A. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med. 2008;205(11):2465–72. doi:10.1084/jem.20080789. PMID:18824584.
   PubMed Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. doi:10.1093/bioinformatics/btp324. PMID:19451168.
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303. doi:10.1101/gr.107524.110. PMID:20644199.
   PubMed Web of Science ®Google Scholar
• DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8. doi:10.1038/ng.806. PMID:21478889.
   PubMed Web of Science ®Google Scholar
• Cingolani P. snpEff: Variant effect prediction". http://snpeff.sourceforge.net; 2012.
   Google Scholar
• Wickham H. ggplot2. Elegant Graphics for Data Analysis Book Use R; 2009.
   Google Scholar
• Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R. Bioinformatics. 2014;30:2811–2. doi:10.1093/bioinformatics/btu393. PMID:24930139.
   PubMed Web of Science ®Google Scholar
• Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011;12:35. doi:10.1186/1471-2105-12-35. PMID:21269502.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088. PMID:23550210.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095. PMID:22588877.
   PubMed Web of Science ®Google Scholar
• Edelmann W, Yang K, Kuraguchi M, Heyer J, Lia M, Kneitz B, Fan K, Brown AM, Lipkin M, Kucherlapati R. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res. 1999;59(6):1301–7. PMID:10096563.
   PubMed Web of Science ®Google Scholar
• Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol. 2016;6:663. doi:10.3389/fimmu.2015.00663. PMID:26834740.
   PubMed Web of Science ®Google Scholar